Skip to main content

Donna Niedzwiecki

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2717, Durham, NC 27710
2424 Erwin Rd, Hock Plaza, Suite 802, Rm 8040, Durham, NC 27705

Overview


Primary interests include clinical trials design and the design and analysis of biomarker and imaging studies especially in the areas of GI cancer, lymphoma, melanoma, transplant and cancer immunotherapy.

Current Appointments & Affiliations


Professor of Biostatistics & Bioinformatics · 2022 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Director, DCI Biostatistics · 2020 - Present Biostatistics & Bioinformatics, Basic Science Departments
Member of the Duke Cancer Institute · 1997 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Journal Article J Clin Oncol · October 10, 2025 PURPOSE: Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR)- ... Full text Link to item Cite

Using Natural Language Processing to Assess Goals-of-Care Conversations for Patients With Cancer.

Conference JCO Clin Cancer Inform · October 2025 PURPOSE: Goals-of-care (GOC) discussions during advanced serious illness and end-of-life (EOL) care are critical. Institutions are increasingly tracking the frequency and timing of GOC documentation, but large-scale content assessments have been limited. W ... Full text Link to item Cite

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

Journal Article Eur J Cancer · September 9, 2025 BACKGROUND: Metastatic recurrence of colorectal cancer (mCRC) after adjuvant therapy may differ biologically from recurrence in untreated mCRC. We examined first-line treatment outcomes of patients within the phase III CALGB/SWOG 80405 (CALGB 80405) and FI ... Full text Link to item Cite
View All Publications

Recent Grants


Serum pro-N-cadherin as an early biomarker of radiation-induced heart disease

ResearchStatistician · Awarded by National Institutes of Health · 2025 - 2030

Project 2: Inflammation and Submucosal Glands During Esophageal Injury and Repair

ResearchCo Investigator · Awarded by Case Western Reserve University · 2023 - 2028

Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas

ResearchCo Investigator · Awarded by National Cancer Institute · 2018 - 2028

View All Grants

Education, Training & Certifications


Yale University · 1984 Ph.D.